You are here

Treatment with salicylate or quinine derivatives

Document
Last amended 
23 June 2015

Tinnitus - Treatment with salicylate or quinine derivatives Factor

Although sensorineural hearing loss or tinnitus may be caused or aggravated by taking salicylate derivatives or quinine derivatives, this effect of such drugs is characteristically reversible once the drug is discontinued. Therefore, the taking of salicylate or quinine derivatives is only a factor in the causation or aggravation of sensorineural hearing loss or tinnitus if the treatment with that drug could not be stopped or replaced by treatment with some other drug. This would not be the case if, for example, a person was taking aspirin for pain relief because other pain relieving medication (eg paracetamol) could be used.

Last reviewed for CCPS 10 June 2012.

Investigative Documents
Type Title PDF Format Word Format
Medical Report
Salicylates or Quinine Derivatives
MR9100.pdf
MR9100.docx
Preliminary questions [16720]

30470 there is some evidence that treatment with salicylate or quinine derivatives may be a factor in the development or worsening of the condition under consideration.

16722 the veteran was undergoing a course of treatment with salicylate or quinine derivatives at the time of the clinical onset or worsening of the condition under consideration.

16723 the veteran was undergoing a course of treatment with salicylate or quinine derivatives at the time of the clinical onset or worsening of the condition under consideration for an illness or injury which is identifiable.

16724 the identified illness or injury is a condition for which treatment with salicylate or quinine derivatives can be ceased or substituted.

16725  the veteran has established the causal connection between the treatment with salicylate or quinine derivatives and VEA service for the condition under consideration.

30439 for the identified illness or injury, the veteran was undergoing a course of treatment with salicylate or quinine derivatives, which were unable to be ceased or substituted, at the time of the clinical onset of the condition under consideration.

16726   the veteran has established the causal connection between the treatment with salicylate or quinine derivatives and VEA service for the clinical onset of the condition under consideration.

30441  the veteran has established the causal connection between the treatment with salicylate or quinine derivatives and operational service for the clinical onset of the condition under consideration.

or

30442  the veteran has established the causal connection between the treatment with salicylate or quinine derivatives and eligible service for the clinical onset of the condition under consideration.

or

7334     the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service.

7335     the condition under consideration permanently worsened.

30440 for the identified illness or injury, the veteran was undergoing a course of treatment with salicylate or quinine derivatives, which were unable to be ceased or substituted, at the time of the clinical worsening of the condition under consideration.

16727   the veteran has established the causal connection between the treatment with salicylate or quinine derivatives and VEA service for the clinical worsening of the condition under consideration.

30443  the veteran has established the causal connection between the treatment with salicylate or quinine derivatives and operational service for the clinical worsening of the condition under consideration.

or

30444  the veteran has established the causal connection between the treatment with salicylate or quinine derivatives and eligible service for the clinical worsening of the condition under consideration.

Clinical onset and operational service [30441]

16728  the identified illness or injury, for which the course of treatment with salicylate or quinine derivatives was undergone, is causally related to operational service.

Clinical onset and eligible service [30442]

16729  the identified illness or injury, for which the course of treatment with salicylate or quinine derivatives was undergone, is causally related to eligible service.

Clinical worsening and operational service [30443]

16728  the identified illness or injury, for which the course of treatment with salicylate or quinine derivatives was undergone, is causally related to operational service.

30445 the clinical onset of the condition under consideration occurred prior to that part of operational service to which the identified illness or injury, for which the course of treatment with salicylate or quinine derivatives was undergone, is causally related.

Clinical worsening and eligible service [30444]

16729  the identified illness or injury, for which the course of treatment with salicylate or quinine derivatives was undergone, is causally related to eligible service.

30446 the clinical onset of the condition under consideration occurred prior to that part of eligible service to which the identified illness or injury, for which the course of treatment with salicylate or quinine derivatives was undergone, is causally related.